Gamma Biosciences invests in Nirrin Technologies

By The Science Advisory Board staff writers

September 24, 2021 -- Gamma Biosciences has made an investment in bioprocessing firm Nirrin Technologies. Terms of the investment were not disclosed.

Gamma will provide support to Nirrin for helping expand customer engagement with the developer and manufacturers of cell and gene therapies, biologics, and vaccines, the company said.

Nirrin's bioprocessing platform uses near-infrared spectroscopy and back-end data processing for applications such as real-time glucose monitoring, cell density in-line measurements, and protein concentration and aggregation, according to Gamma Biosciences.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.